CATALOGO DEI PRODOTTI DELLA RICERCA

CINGARLINI, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.437
EU - Europa 5.270
AS - Asia 3.473
SA - Sud America 471
Continente sconosciuto - Info sul continente non disponibili 154
AF - Africa 106
OC - Oceania 11
Totale 14.922
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.284
RU - Federazione Russa 1.974
SG - Singapore 1.191
CN - Cina 1.175
GB - Regno Unito 1.019
IT - Italia 681
BR - Brasile 372
SE - Svezia 325
DE - Germania 317
VN - Vietnam 288
IE - Irlanda 265
HK - Hong Kong 264
FR - Francia 237
FI - Finlandia 174
BD - Bangladesh 119
KR - Corea 101
CA - Canada 84
IN - India 70
TR - Turchia 55
JP - Giappone 50
NL - Olanda 49
UA - Ucraina 42
MX - Messico 34
ES - Italia 33
AR - Argentina 32
BE - Belgio 29
PL - Polonia 29
ID - Indonesia 26
NG - Nigeria 25
IQ - Iraq 24
AT - Austria 19
MA - Marocco 18
ZA - Sudafrica 17
IR - Iran 15
CL - Cile 13
CO - Colombia 13
PK - Pakistan 13
VE - Venezuela 12
AE - Emirati Arabi Uniti 11
LT - Lituania 11
EC - Ecuador 10
SA - Arabia Saudita 10
UZ - Uzbekistan 10
AU - Australia 9
PH - Filippine 9
ET - Etiopia 8
LV - Lettonia 8
MY - Malesia 8
AZ - Azerbaigian 7
CH - Svizzera 7
EG - Egitto 7
JO - Giordania 7
PY - Paraguay 7
TN - Tunisia 7
CR - Costa Rica 6
GR - Grecia 6
JM - Giamaica 6
KE - Kenya 5
PE - Perù 5
RO - Romania 5
UY - Uruguay 5
BJ - Benin 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
DZ - Algeria 4
SI - Slovenia 4
TG - Togo 4
GT - Guatemala 3
HN - Honduras 3
HR - Croazia 3
IL - Israele 3
KW - Kuwait 3
MK - Macedonia 3
NI - Nicaragua 3
PA - Panama 3
PR - Porto Rico 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
TH - Thailandia 3
AL - Albania 2
BS - Bahamas 2
BY - Bielorussia 2
CM - Camerun 2
EE - Estonia 2
HU - Ungheria 2
KZ - Kazakistan 2
NO - Norvegia 2
NP - Nepal 2
PT - Portogallo 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
DM - Dominica 1
EU - Europa 1
GD - Grenada 1
Totale 14.756
Salva come PNG Salva come JPEG
Città #
Southend 866
Moscow 736
Singapore 636
Chandler 614
Ashburn 572
Dallas 566
San Jose 444
Verona 269
Hong Kong 256
Dublin 255
Jacksonville 247
Beijing 232
Ann Arbor 214
Woodbridge 204
New York 174
The Dalles 131
Los Angeles 122
Houston 96
Ho Chi Minh City 95
Council Bluffs 93
Munich 84
Jinan 76
Lawrence 76
Princeton 76
Wilmington 73
Shenyang 70
Helsinki 68
Hanoi 63
São Paulo 58
Tianjin 56
Nanjing 53
Milan 51
Santa Clara 49
Tokyo 44
Orem 43
Buffalo 42
Hebei 40
Changsha 35
Columbus 35
Guangzhou 34
Haikou 34
London 32
Montreal 32
Redmond 32
Redondo Beach 31
Zhengzhou 31
Brussels 29
Denver 27
Abuja 25
Bologna 25
Seattle 25
Sindelfingen 24
Warsaw 24
Nanchang 23
Taiyuan 23
Hangzhou 22
Seoul 22
Toronto 22
Turku 22
Chennai 21
Chicago 20
Ningbo 20
Taizhou 20
Lancaster 19
Paris 19
Redwood City 19
Amsterdam 18
San Francisco 18
Atlanta 17
Frankfurt am Main 17
Shanghai 17
Brooklyn 16
Falkenstein 16
Jiaxing 15
Mexico City 15
Phoenix 15
Rio de Janeiro 15
Da Nang 14
Manchester 14
Rome 14
Stockholm 14
Kent 13
Poplar 13
Boardman 12
Dong Ket 12
Jakarta 12
Johannesburg 12
Turin 12
Washington 12
Barnet 10
Curitiba 10
Fuzhou 10
Mumbai 10
New Delhi 10
Norwalk 10
Tashkent 10
Brescia 9
Charlotte 9
Florence 9
Madrid 9
Totale 9.030
Salva come PNG Salva come JPEG
Nome #
Somatostatin analogs for resectable pancreatic neuroendocrine tumors in high-risk surgical patients: Data from a single-center cohort 298
Anti PSMA immunotoxins activity against prostate cancer cell lines. 292
Whole-genome landscape of pancreatic neuroendocrine tumours 282
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. 274
Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? 259
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 250
Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma 241
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer 241
Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity? Results from a Single-Center Surgical Series 241
CT Enhancement and 3D Texture Analysis of Pancreatic Neuroendocrine Neoplasms 241
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. 237
The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs): Time-trend and Outcome Analysis From 587 Consecutive Resections at a High-volume Institution. 236
3D-CT texture analysis of neuroendocrine pancreatic neoplasms 236
Characterization of a new anti PSCA monoclonal antibody and scFv fragment for diagnosis and immunotherapy of prostate, pancreatic and bladder carcinoma. 229
Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study 223
Comparison of imaging-based and pathological dimensions in pancreatic neuroendocrine tumors 221
A prospective non-randomised single-center study comparing laparoscopic and robotic distal pancreatectomy 220
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer 214
Anti-prostate specific membrane antigen targeted gold nanoparticles in tumor therapy and diagnosis 212
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi 210
Production of a biotinylated anti-PSMA single-chain antibody fragment (scFv) for imaging and radioimmunotherapy 209
EpCAM a possible target for immunotoxin treatments of PSMA positive and negative prostate cancer cells 207
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 205
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 200
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 198
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumor cells by activating the MAPK pathways. 196
Ingegnerizzazione di un vettore per espressione di frammenti anticorpali (scFv) biotinilati in procarioti, purificazione ed analisi funzionale 195
ESGAR 2016 Book of Abstracts 194
Dual-tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT scan and G1-G2 non-functioning pancreatic neuroendocrine tumors: A single-center retrospective evaluation of 124 non-metastatic resected cases 194
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 194
Investigation of Properties of Anti-Prostate Specific Membrane Antigen-targeted Gold Nanoparticles as Drug Carriers in Tumor Therapy 192
Role of Combined Ga-68-DOTATOC and F-18-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors Implications for Managing Surgical Decisions 192
Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment 192
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 192
Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage 192
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 188
Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components 186
Produzione e validazione preclinica di un anticorpo anti-PSMA per diagnostica ed immunotargeting 185
Tumor Targeting with Guided Silica Nanopartilces for Prostate Cancer Therapy 185
The prostate specific membrane antigen regulates the expression of IL-6 and CCL-5 in prostate tumour cells by activating the MAPK pathways 185
Liver Tumor Burden in Pancreatic Neuroendocrine Tumors: CT Features and Texture Analysis in the Prediction of Tumor Grade and 18F-FDG Uptake 184
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 179
Generazione di nuovi anticorpi anti prostate stem cell antigen (PSCA) e loro caratterizzazione al fine di un futuro utilizzo nella terapia e nella diagnosi dei carcinomi prostatico, pancreatico e della vescica 178
The development of PARP as a successful target for cancer therapy 177
Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors 177
Prognostication and response assessment in liver and pancreatic tumors: The new imaging 176
Pathological complete response in a patient affected by multiple synchronous, breast and lung primary malignancies: a case report and review of the literature 169
Imaging presentation of pancreatic neuroendocrine neoplasms 167
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 166
Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors: a retrospective analysis of 110 cases 165
Patterns of recurrence after resection for pancreatic neuroendocrine tumors: who, when, and where? 164
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours 164
Surgery for pancreatic neuroendocrine tumors during the COVID-19 pandemic: a retrospective cohort from a high-volume center 163
Histogram analysis of ADC maps: assessment of intra-tumoral heterogeneity and correlation with the biological behavior of pancreatic neuroendocrine neoplasms 163
Preclinical studies of a new anti-psma (prostate specific membrane antigen) antibody for diagnosis and immunotargeting 162
Pancreatic neuroendocrine neoplasms: MRI features and correlation with their histological grade 162
Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof 161
Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms 157
Digital Subtraction of Magnetic Resonance Images Improves Detection and Characterization of Pancreatic Neuroendocrine Neoplasms 156
Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants 156
Prognostic Stratification and Therapeutic Response Assessment in Liver and Pancreatic Tumors: the New Imaging 153
Solid non-functioning endocrine tumors of the pancreas: correlating computed tomography and pathology 150
Clinical presentation, genotype-phenotype correlations, and outcome of pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome 150
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association 146
Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience 141
Differentiation of pancreatic neuroendocrine tumor grade comparing 3D CT texture analysis and relative CT enhancement ratios 140
Is Laparoscopic CME Right Hemicolectomy an Optimal Indication for NET of the Right Colon and Terminal Ileum? 136
Profiling mTOR pathway in neuroendocrine tumors 135
Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology 134
Minimally Invasive Surgery for Pancreatic Neuroendocrine Tumors: Why Not? 130
Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives 130
Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment 128
Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring 123
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models 122
Pancreatic Neuroendocrine Neoplasms: Clinical Value of Diffusion-Weighted Imaging 118
Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres) 116
Normal Tissue Perfusion Changes During Everolimus Treatment: Preliminary Results from a Functional Vascular Study 111
Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups 105
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size 102
Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors 101
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine 95
Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant? 85
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET) 77
Multi-omic profiles of neuroendocrine neoplasms of the pancreas: an integrated landscape 7
Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors 3
Totale 14.922
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.599
article - articoli 33.363
book - libri 0
conference - conferenze 13.234
curatela - curatele 0
other - altro 532
patent - brevetti 1.024
selected - selezionate 0
volume - volumi 446
Totale 97.198
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022721 0 256 18 70 37 17 14 44 23 18 53 171
2022/20231.625 96 211 148 287 108 429 38 88 173 9 25 13
2023/2024835 29 66 75 82 90 166 25 50 9 65 144 34
2024/20251.933 104 112 108 273 99 76 104 88 279 137 182 371
2025/20266.618 412 354 507 1.112 1.736 403 526 340 514 383 134 197
2026/2027288 254 34 0 0 0 0 0 0 0 0 0 0
Totale 14.922